Xalipat-50/Xalipat-100 Dosage & Drug Information

Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Special Precautions Use In Pregnancy & Lactation Adverse Reactions Drug Interactions Caution For Usage Storage MIMS Class ATC Classification Regulatory Classification Presentation/Packing

Concise Prescribing Info

Contents

Oxaliplatin

Indications/Uses

Metastatic CRC after failure of treatment w/ fluoropyrimidines as monochemotherapy or along w/ fluoropyrimidines.

Click to view Xalipat-50/Xalipat-100 detailed prescribing information

Dosage/Direction for Use

As single agent 130 mg/m² as continuous IV infusion over 2-6 hr, may be repeated at an interval of 3 wk. In combination therapy Day 1: Administer 85 mg/m² concurrently w/ leucovorin 200 mg/m² by IV infusion over 2 hr, then fluorouracil 400 mg/m² by IV inj over 2-4 min followed by fluorouracil 600 mg/m² by IV infusion over 22 hr. Day 2: Administer leucovorin 200 mg/m² by IV infusion over 2 hr, then fluorouracil 400 mg/m² by IV inj over 2-4 min followed by fluorouracil 600 mg/m² by IV infusion over 22 hr. Repeat regimen at interval of 2 wk.

Click to view Xalipat-50/Xalipat-100 detailed prescribing information

Overdosage

View Xalipat-50/Xalipat-100 overdosage for action to be taken in the event of an overdose.

Contraindications

History of severe allergy. Severe pre-existing peripheral neuropathy. Severe renal dysfunction (CrCl <30 mL/min). Pregnancy & lactation.

Click to view Xalipat-50/Xalipat-100 detailed prescribing information

Special Precautions

Hypersensitivity to other platinum agents. Assess differential WBC count, Hb, platelet count, ALT, AST, bilirubin & creatinine levels before each Xalipat cycle. Probable carcinogen. Renal impairment.

Click to view Xalipat-50/Xalipat-100 detailed prescribing information

Use In Pregnancy & Lactation

Click to view Xalipat-50/Xalipat-100 detailed prescribing information

Adverse Reactions

Sensory neuropathy; anaemia; fever; nausea & vomiting; liver function abnormalities; infections; alopecia; pharyngolaryngeal dysesthesia.

Click to view Xalipat-50/Xalipat-100 detailed prescribing information

Drug Interactions

Potentiate irinotecan inhibition of acetylcholinesterase. Synergistic w/ fluorouracil & SN-38 (active irinotecan metabolite).

Click to view Xalipat-50/Xalipat-100 detailed prescribing information

Caution For Usage

For caution against possible variation of physical aspect of medicine... Click to view Xalipat-50/Xalipat-100 detailed prescribing information

Storage

View Xalipat-50/Xalipat-100 storage conditions for details to ensure optimal shelf-life.

Description

View Xalipat-50/Xalipat-100 description for details of the chemical structure and excipients (inactive components).

Action

View Xalipat-50/Xalipat-100 mechanism of action for pharmacodynamics and pharmacokinetics details.

MIMS Class

Cytotoxic Chemotherapy

ATC Classification

L01XA03 - oxaliplatin ; Belongs to the class of platinum-containing antineoplastic agents. Used in the treatment of cancer.

Regulatory Classification

POM

Presentation/Packing

Form

Xalipat-100 inj 100 mg/50 mL

Packing/Price

50 mL x 1's

Form

Xalipat-50 inj 50 mg/25 mL

Packing/Price

25 mL x 1's

Xalipat-50/Xalipat-100

oxaliplatin

Manufacturer:

Khandelwal Lab

Distributor:

Ni Lay Naing